CA2988982A1 - Anti-cd33 antibodies and methods of use thereof - Google Patents
Anti-cd33 antibodies and methods of use thereof Download PDFInfo
- Publication number
- CA2988982A1 CA2988982A1 CA2988982A CA2988982A CA2988982A1 CA 2988982 A1 CA2988982 A1 CA 2988982A1 CA 2988982 A CA2988982 A CA 2988982A CA 2988982 A CA2988982 A CA 2988982A CA 2988982 A1 CA2988982 A1 CA 2988982A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- antibody
- seq
- cells
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 70
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims abstract description 165
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims abstract description 130
- -1 e.g. Proteins 0.000 claims abstract description 50
- 102000056982 human CD33 Human genes 0.000 claims abstract description 36
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 419
- 210000004027 cell Anatomy 0.000 claims description 203
- 206010028980 Neoplasm Diseases 0.000 claims description 178
- 125000000539 amino acid group Chemical group 0.000 claims description 176
- 231100001221 nontumorigenic Toxicity 0.000 claims description 144
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 143
- 108090000623 proteins and genes Proteins 0.000 claims description 122
- 102000004169 proteins and genes Human genes 0.000 claims description 118
- 239000003446 ligand Substances 0.000 claims description 113
- 210000004443 dendritic cell Anatomy 0.000 claims description 106
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 91
- 230000003247 decreasing effect Effects 0.000 claims description 86
- 230000001965 increasing effect Effects 0.000 claims description 82
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 77
- 201000010099 disease Diseases 0.000 claims description 75
- 210000000274 microglia Anatomy 0.000 claims description 72
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 70
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 67
- 230000001413 cellular effect Effects 0.000 claims description 66
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 65
- 239000003018 immunosuppressive agent Substances 0.000 claims description 65
- 210000000066 myeloid cell Anatomy 0.000 claims description 65
- 210000002540 macrophage Anatomy 0.000 claims description 62
- 230000007423 decrease Effects 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 47
- 210000000440 neutrophil Anatomy 0.000 claims description 45
- 102000004127 Cytokines Human genes 0.000 claims description 42
- 108090000695 Cytokines Proteins 0.000 claims description 42
- 238000002560 therapeutic procedure Methods 0.000 claims description 38
- 102000005962 receptors Human genes 0.000 claims description 37
- 108020003175 receptors Proteins 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 35
- 230000008595 infiltration Effects 0.000 claims description 35
- 238000001764 infiltration Methods 0.000 claims description 35
- 210000001185 bone marrow Anatomy 0.000 claims description 33
- 230000002401 inhibitory effect Effects 0.000 claims description 33
- 102000007073 Sialic Acid Binding Immunoglobulin-like Lectins Human genes 0.000 claims description 30
- 108010047827 Sialic Acid Binding Immunoglobulin-like Lectins Proteins 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 29
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 29
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 29
- 230000003993 interaction Effects 0.000 claims description 29
- 210000001616 monocyte Anatomy 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 28
- 210000003289 regulatory T cell Anatomy 0.000 claims description 27
- 230000005909 tumor killing Effects 0.000 claims description 27
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 26
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 26
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 25
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 25
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 24
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 24
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 24
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 24
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 24
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 24
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 24
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 24
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 24
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 24
- 210000003690 classically activated macrophage Anatomy 0.000 claims description 24
- 230000005764 inhibitory process Effects 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 24
- 208000024827 Alzheimer disease Diseases 0.000 claims description 22
- 239000012829 chemotherapy agent Substances 0.000 claims description 22
- 230000004083 survival effect Effects 0.000 claims description 22
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 238000009169 immunotherapy Methods 0.000 claims description 21
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 20
- 108700028369 Alleles Proteins 0.000 claims description 20
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 20
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 20
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims description 20
- 229960002949 fluorouracil Drugs 0.000 claims description 20
- 208000014674 injury Diseases 0.000 claims description 19
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 18
- 230000002708 enhancing effect Effects 0.000 claims description 18
- 210000003714 granulocyte Anatomy 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 210000002997 osteoclast Anatomy 0.000 claims description 18
- 230000035755 proliferation Effects 0.000 claims description 18
- 102100038078 CD276 antigen Human genes 0.000 claims description 17
- 101710185679 CD276 antigen Proteins 0.000 claims description 17
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 17
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 17
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 17
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 17
- 239000000556 agonist Substances 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000010494 dissociation reaction Methods 0.000 claims description 17
- 230000005593 dissociations Effects 0.000 claims description 17
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 17
- KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 claims description 16
- 102000043334 C9orf72 Human genes 0.000 claims description 16
- 108700030955 C9orf72 Proteins 0.000 claims description 16
- 206010012289 Dementia Diseases 0.000 claims description 16
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims description 16
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 108020001507 fusion proteins Proteins 0.000 claims description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 15
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 15
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims description 15
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 15
- 208000032839 leukemia Diseases 0.000 claims description 15
- 239000003053 toxin Substances 0.000 claims description 15
- 231100000765 toxin Toxicity 0.000 claims description 15
- 108700012359 toxins Proteins 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 230000000692 anti-sense effect Effects 0.000 claims description 14
- 230000002519 immonomodulatory effect Effects 0.000 claims description 14
- 238000001727 in vivo Methods 0.000 claims description 14
- 229930186217 Glycolipid Natural products 0.000 claims description 13
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 13
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 13
- 210000000822 natural killer cell Anatomy 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 13
- 230000004614 tumor growth Effects 0.000 claims description 13
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 12
- 102000002698 KIR Receptors Human genes 0.000 claims description 12
- 108010043610 KIR Receptors Proteins 0.000 claims description 12
- 210000004322 M2 macrophage Anatomy 0.000 claims description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 12
- 230000004936 stimulating effect Effects 0.000 claims description 12
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 11
- 206010005003 Bladder cancer Diseases 0.000 claims description 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 102100027207 CD27 antigen Human genes 0.000 claims description 11
- 101150013553 CD40 gene Proteins 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 11
- 206010014733 Endometrial cancer Diseases 0.000 claims description 11
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 11
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 11
- 102100031351 Galectin-9 Human genes 0.000 claims description 11
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 11
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 11
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 11
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 11
- 206010038389 Renal cancer Diseases 0.000 claims description 11
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 11
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims description 11
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 11
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 11
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 11
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 11
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 230000000259 anti-tumor effect Effects 0.000 claims description 11
- 208000029742 colonic neoplasm Diseases 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000006870 function Effects 0.000 claims description 11
- 229960000578 gemtuzumab Drugs 0.000 claims description 11
- 210000002865 immune cell Anatomy 0.000 claims description 11
- 201000010982 kidney cancer Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 230000002025 microglial effect Effects 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 206010038038 rectal cancer Diseases 0.000 claims description 11
- 201000001275 rectum cancer Diseases 0.000 claims description 11
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 11
- 201000007444 renal pelvis carcinoma Diseases 0.000 claims description 11
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 11
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 10
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 10
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 10
- 101000795107 Homo sapiens Triggering receptor expressed on myeloid cells 1 Proteins 0.000 claims description 10
- 101000795117 Homo sapiens Triggering receptor expressed on myeloid cells 2 Proteins 0.000 claims description 10
- 102000017761 Interleukin-33 Human genes 0.000 claims description 10
- 108010067003 Interleukin-33 Proteins 0.000 claims description 10
- 229940123237 Taxane Drugs 0.000 claims description 10
- 102100029681 Triggering receptor expressed on myeloid cells 1 Human genes 0.000 claims description 10
- 102100029678 Triggering receptor expressed on myeloid cells 2 Human genes 0.000 claims description 10
- 108090000848 Ubiquitin Proteins 0.000 claims description 10
- 102000044159 Ubiquitin Human genes 0.000 claims description 10
- 230000001270 agonistic effect Effects 0.000 claims description 10
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 229960004117 capecitabine Drugs 0.000 claims description 10
- 229960004562 carboplatin Drugs 0.000 claims description 10
- 229960004397 cyclophosphamide Drugs 0.000 claims description 10
- 229940087477 ellence Drugs 0.000 claims description 10
- 229960001904 epirubicin Drugs 0.000 claims description 10
- 229960005277 gemcitabine Drugs 0.000 claims description 10
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 10
- 230000005012 migration Effects 0.000 claims description 10
- 238000013508 migration Methods 0.000 claims description 10
- 230000000770 proinflammatory effect Effects 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 230000011664 signaling Effects 0.000 claims description 9
- 102000013498 tau Proteins Human genes 0.000 claims description 9
- 108010026424 tau Proteins Proteins 0.000 claims description 9
- IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 claims description 8
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 8
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 8
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 8
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 8
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- 102000007372 Ataxin-1 Human genes 0.000 claims description 8
- 108010032963 Ataxin-1 Proteins 0.000 claims description 8
- 102000002785 Ataxin-10 Human genes 0.000 claims description 8
- 108010043914 Ataxin-10 Proteins 0.000 claims description 8
- 102000007371 Ataxin-3 Human genes 0.000 claims description 8
- 108010032947 Ataxin-3 Proteins 0.000 claims description 8
- 102000007368 Ataxin-7 Human genes 0.000 claims description 8
- 108010032953 Ataxin-7 Proteins 0.000 claims description 8
- 102100026565 Ataxin-8 Human genes 0.000 claims description 8
- 101710147490 Ataxin-8 Proteins 0.000 claims description 8
- 102000007370 Ataxin2 Human genes 0.000 claims description 8
- 108010032951 Ataxin2 Proteins 0.000 claims description 8
- 102000014461 Ataxins Human genes 0.000 claims description 8
- 108010078286 Ataxins Proteins 0.000 claims description 8
- 101800001288 Atrial natriuretic factor Proteins 0.000 claims description 8
- 101800001890 Atrial natriuretic peptide Proteins 0.000 claims description 8
- 102400001282 Atrial natriuretic peptide Human genes 0.000 claims description 8
- 101150014718 C9orf72 gene Proteins 0.000 claims description 8
- 102000055006 Calcitonin Human genes 0.000 claims description 8
- 108060001064 Calcitonin Proteins 0.000 claims description 8
- 102000015833 Cystatin Human genes 0.000 claims description 8
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 8
- 102000004878 Gelsolin Human genes 0.000 claims description 8
- 108090001064 Gelsolin Proteins 0.000 claims description 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 8
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 102000003814 Interleukin-10 Human genes 0.000 claims description 8
- 108090000174 Interleukin-10 Proteins 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 102400001156 Medin Human genes 0.000 claims description 8
- 101800003015 Medin Proteins 0.000 claims description 8
- 102000016943 Muramidase Human genes 0.000 claims description 8
- 108010014251 Muramidase Proteins 0.000 claims description 8
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 8
- 108010071690 Prealbumin Proteins 0.000 claims description 8
- 102000029797 Prion Human genes 0.000 claims description 8
- 108091000054 Prion Proteins 0.000 claims description 8
- 108010057464 Prolactin Proteins 0.000 claims description 8
- 102000003946 Prolactin Human genes 0.000 claims description 8
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 8
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 8
- 102000054727 Serum Amyloid A Human genes 0.000 claims description 8
- 108700028909 Serum Amyloid A Proteins 0.000 claims description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 8
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 8
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 claims description 8
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 claims description 8
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 8
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 8
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 8
- 102000009190 Transthyretin Human genes 0.000 claims description 8
- 201000004810 Vascular dementia Diseases 0.000 claims description 8
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 8
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 claims description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 8
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 8
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 8
- 108700006666 betaIG-H3 Proteins 0.000 claims description 8
- 108091006374 cAMP receptor proteins Proteins 0.000 claims description 8
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 8
- 229960004015 calcitonin Drugs 0.000 claims description 8
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 claims description 8
- 108050004038 cystatin Proteins 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 210000004558 lewy body Anatomy 0.000 claims description 8
- 239000004325 lysozyme Substances 0.000 claims description 8
- 229960000274 lysozyme Drugs 0.000 claims description 8
- 235000010335 lysozyme Nutrition 0.000 claims description 8
- 210000000944 nerve tissue Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 229940097325 prolactin Drugs 0.000 claims description 8
- 230000000722 protumoral effect Effects 0.000 claims description 8
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 8
- 201000002510 thyroid cancer Diseases 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 claims description 7
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 108091007960 PI3Ks Proteins 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 108020004459 Small interfering RNA Proteins 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 7
- 229940022399 cancer vaccine Drugs 0.000 claims description 7
- 238000009566 cancer vaccine Methods 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 230000006028 immune-suppresssive effect Effects 0.000 claims description 7
- 229950002950 lintuzumab Drugs 0.000 claims description 7
- 210000005210 lymphoid organ Anatomy 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 claims description 6
- 108010066676 Abrin Proteins 0.000 claims description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 6
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 6
- 102100039496 Choline transporter-like protein 4 Human genes 0.000 claims description 6
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 6
- 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 102000003839 Human Proteins Human genes 0.000 claims description 6
- 108090000144 Human Proteins Proteins 0.000 claims description 6
- 102100034980 ICOS ligand Human genes 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 108090001007 Interleukin-8 Proteins 0.000 claims description 6
- 102000004890 Interleukin-8 Human genes 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 6
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 6
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 claims description 6
- 108010039491 Ricin Proteins 0.000 claims description 6
- 229960005305 adenosine Drugs 0.000 claims description 6
- 230000001640 apoptogenic effect Effects 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 150000002270 gangliosides Chemical class 0.000 claims description 6
- 229940127121 immunoconjugate Drugs 0.000 claims description 6
- 230000002147 killing effect Effects 0.000 claims description 6
- 229960001592 paclitaxel Drugs 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 5
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 5
- 101710155855 C-C motif chemokine 4 Proteins 0.000 claims description 5
- 102100021984 C-C motif chemokine 4-like Human genes 0.000 claims description 5
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims description 5
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 5
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims description 5
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 108090000177 Interleukin-11 Proteins 0.000 claims description 5
- 102000003815 Interleukin-11 Human genes 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 108050003558 Interleukin-17 Proteins 0.000 claims description 5
- 102000013691 Interleukin-17 Human genes 0.000 claims description 5
- 102000003810 Interleukin-18 Human genes 0.000 claims description 5
- 108090000171 Interleukin-18 Proteins 0.000 claims description 5
- 108010065637 Interleukin-23 Proteins 0.000 claims description 5
- 102000043136 MAP kinase family Human genes 0.000 claims description 5
- 108091054455 MAP kinase family Proteins 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 239000003862 glucocorticoid Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 108090000681 interleukin 20 Proteins 0.000 claims description 5
- 102000004114 interleukin 20 Human genes 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 4
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 4
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 4
- 230000003042 antagnostic effect Effects 0.000 claims description 4
- 229940124650 anti-cancer therapies Drugs 0.000 claims description 4
- 238000011319 anticancer therapy Methods 0.000 claims description 4
- 230000008499 blood brain barrier function Effects 0.000 claims description 4
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 210000000225 synapse Anatomy 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 230000032258 transport Effects 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 3
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 claims description 3
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 claims description 3
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 claims description 3
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 claims description 3
- 102100021703 C3a anaphylatoxin chemotactic receptor Human genes 0.000 claims description 3
- 108010017009 CD11b Antigen Proteins 0.000 claims description 3
- 102100035904 Caspase-1 Human genes 0.000 claims description 3
- 108700032819 Croton tiglium crotin II Proteins 0.000 claims description 3
- 102100031237 Cystatin-A Human genes 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 3
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 claims description 3
- 102100033039 Glutathione peroxidase 1 Human genes 0.000 claims description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 3
- 102100028006 Heme oxygenase 1 Human genes 0.000 claims description 3
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 claims description 3
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 claims description 3
- 101000896583 Homo sapiens C3a anaphylatoxin chemotactic receptor Proteins 0.000 claims description 3
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 claims description 3
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 claims description 3
- 101001014936 Homo sapiens Glutathione peroxidase 1 Proteins 0.000 claims description 3
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 claims description 3
- 101001046668 Homo sapiens Integrin alpha-X Proteins 0.000 claims description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 claims description 3
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 3
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 3
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 3
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 102000049772 Interleukin-16 Human genes 0.000 claims description 3
- 101800003050 Interleukin-16 Proteins 0.000 claims description 3
- 102000004388 Interleukin-4 Human genes 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 3
- 102100034238 Linker for activation of T-cells family member 2 Human genes 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 102100038556 Membrane-spanning 4-domains subfamily A member 4A Human genes 0.000 claims description 3
- 229930192392 Mitomycin Natural products 0.000 claims description 3
- 102220556120 Myeloid cell surface antigen CD33_A14V_mutation Human genes 0.000 claims description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 3
- 108091006236 SLC7A7 Proteins 0.000 claims description 3
- 108091006238 SLC7A8 Proteins 0.000 claims description 3
- 240000003946 Saponaria officinalis Species 0.000 claims description 3
- 230000006052 T cell proliferation Effects 0.000 claims description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 3
- 101150069237 TYROBP gene Proteins 0.000 claims description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 102100032726 Y+L amino acid transporter 1 Human genes 0.000 claims description 3
- 229930183665 actinomycin Natural products 0.000 claims description 3
- 108010001818 alpha-sarcin Proteins 0.000 claims description 3
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 108010056028 auromycin Proteins 0.000 claims description 3
- 229910052797 bismuth Inorganic materials 0.000 claims description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims description 3
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims description 3
- 229930195731 calicheamicin Natural products 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 230000022534 cell killing Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 3
- 229960000975 daunorubicin Drugs 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 3
- 229930188854 dolastatin Natural products 0.000 claims description 3
- 230000003828 downregulation Effects 0.000 claims description 3
- 229960005501 duocarmycin Drugs 0.000 claims description 3
- 229930184221 duocarmycin Natural products 0.000 claims description 3
- 108010028531 enomycin Proteins 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 claims description 3
- 229960005542 ethidium bromide Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 108091008042 inhibitory receptors Proteins 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 108010010621 modeccin Proteins 0.000 claims description 3
- 230000015286 negative regulation of phagocytosis Effects 0.000 claims description 3
- 108010076042 phenomycin Proteins 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- 229910052727 yttrium Inorganic materials 0.000 claims description 3
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 claims description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims description 2
- 101000836877 Homo sapiens Sialic acid-binding Ig-like lectin 11 Proteins 0.000 claims description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 claims description 2
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 claims description 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 2
- 101000743488 Homo sapiens V-set and immunoglobulin domain-containing protein 4 Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 2
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 claims description 2
- 102000015728 Mucins Human genes 0.000 claims description 2
- 108010063954 Mucins Proteins 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100027125 Sialic acid-binding Ig-like lectin 11 Human genes 0.000 claims description 2
- 102100029957 Sialic acid-binding Ig-like lectin 5 Human genes 0.000 claims description 2
- 101710110535 Sialic acid-binding Ig-like lectin 5 Proteins 0.000 claims description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 claims description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 claims description 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102100038296 V-set and immunoglobulin domain-containing protein 4 Human genes 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- GBVKRUOMSUTVPW-AHNVSIPUSA-N chembl1089636 Chemical compound N([C@H]([C@@H](OC(=O)CCC(=O)N[C@@H](C(O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCNC(=O)CCC(=O)O[C@H]([C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 GBVKRUOMSUTVPW-AHNVSIPUSA-N 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000011393 cytotoxic chemotherapy Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- 230000037041 intracellular level Effects 0.000 claims description 2
- 229940051875 mucins Drugs 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 108010046239 paclitaxel-Angiopep-2 conjugate Proteins 0.000 claims description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 2
- 108010043655 penetratin Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 108010011110 polyarginine Proteins 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000002626 targeted therapy Methods 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 5
- 102100026882 Alpha-synuclein Human genes 0.000 claims 3
- 229940009456 adriamycin Drugs 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 claims 3
- 229940063683 taxotere Drugs 0.000 claims 3
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 101150065475 C1QA gene Proteins 0.000 claims 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 102100036721 Insulin receptor Human genes 0.000 claims 1
- 241000282842 Lama glama Species 0.000 claims 1
- 102000012404 Orosomucoid Human genes 0.000 claims 1
- 108010061952 Orosomucoid Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract 2
- 235000018102 proteins Nutrition 0.000 description 93
- 230000000875 corresponding effect Effects 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 22
- 208000003476 primary myelofibrosis Diseases 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 208000001089 Multiple system atrophy Diseases 0.000 description 8
- 102000003923 Protein Kinase C Human genes 0.000 description 8
- 108090000315 Protein Kinase C Proteins 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 206010028537 myelofibrosis Diseases 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 7
- 101800001718 Amyloid-beta protein Proteins 0.000 description 7
- ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 7
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000038030 PI3Ks Human genes 0.000 description 6
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
- 206010051226 Campylobacter infection Diseases 0.000 description 5
- 241000606768 Haemophilus influenzae Species 0.000 description 5
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 241000588653 Neisseria Species 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 208000030852 Parasitic disease Diseases 0.000 description 5
- 208000032536 Pseudomonas Infections Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 5
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 5
- 102000003802 alpha-Synuclein Human genes 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000004055 small Interfering RNA Substances 0.000 description 5
- 102000009076 src-Family Kinases Human genes 0.000 description 5
- 108010087686 src-Family Kinases Proteins 0.000 description 5
- 208000009137 Behcet syndrome Diseases 0.000 description 4
- 208000006547 Central Nervous System Lupus Vasculitis Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 4
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 4
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 4
- 208000001860 Eye Infections Diseases 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 208000029725 Metabolic bone disease Diseases 0.000 description 4
- 208000021320 Nasu-Hakola disease Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000010191 Osteitis Deformans Diseases 0.000 description 4
- 208000027067 Paget disease of bone Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 201000007737 Retinal degeneration Diseases 0.000 description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 4
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 4
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 208000017733 acquired polycythemia vera Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000016738 bone Paget disease Diseases 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000011235 central nervous system lupus Diseases 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 208000013044 corticobasal degeneration disease Diseases 0.000 description 4
- 201000006517 essential tremor Diseases 0.000 description 4
- 208000011323 eye infectious disease Diseases 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 102000007863 pattern recognition receptors Human genes 0.000 description 4
- 108010089193 pattern recognition receptors Proteins 0.000 description 4
- 208000031334 polycystic lipomembranous osteodysplasia with sclerosing leukoencephaly Diseases 0.000 description 4
- 208000037244 polycythemia vera Diseases 0.000 description 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 4
- 230000004258 retinal degeneration Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 208000020431 spinal cord injury Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 3
- 102000013264 Interleukin-23 Human genes 0.000 description 3
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 3
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 108090000630 Oncostatin M Proteins 0.000 description 3
- 102100031942 Oncostatin-M Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 description 3
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 3
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 3
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 3
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 210000004990 primary immune cell Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 108091007381 CBL proteins Proteins 0.000 description 2
- 101150044797 CD33 gene Proteins 0.000 description 2
- 231100000491 EC50 Toxicity 0.000 description 2
- 102000004662 Elongin Human genes 0.000 description 2
- 108010003751 Elongin Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000055251 Proto-Oncogene Proteins c-cbl Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108700027337 Suppressor of Cytokine Signaling 3 Proteins 0.000 description 2
- 102100024283 Suppressor of cytokine signaling 3 Human genes 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 102000007238 Transferrin Receptors Human genes 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102210007708 rs3826656 Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 1
- 208000022099 Alzheimer disease 2 Diseases 0.000 description 1
- 208000000340 Alzheimer disease type 1 Diseases 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000998126 Homo sapiens Interleukin-36 beta Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 102100033498 Interleukin-36 beta Human genes 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101000863881 Mus musculus Sialic acid-binding Ig-like lectin 5 Proteins 0.000 description 1
- 101710147545 Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102000017954 Nuclear factor of activated T cells (NFAT) Human genes 0.000 description 1
- 108050007058 Nuclear factor of activated T cells (NFAT) Proteins 0.000 description 1
- 108010055279 Oncogene Protein v-cbl Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000000886 SPRY domains Human genes 0.000 description 1
- 108050007917 SPRY domains Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000000551 Syk Kinase Human genes 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 101710128901 Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 201000002687 childhood acute myeloid leukemia Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 230000004063 proteosomal degradation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562175152P | 2015-06-12 | 2015-06-12 | |
| US62/175,152 | 2015-06-12 | ||
| US201562241701P | 2015-10-14 | 2015-10-14 | |
| US62/241,701 | 2015-10-14 | ||
| PCT/US2016/037108 WO2016201388A2 (en) | 2015-06-12 | 2016-06-11 | Anti-cd33 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2988982A1 true CA2988982A1 (en) | 2016-12-15 |
Family
ID=56204010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988982A Abandoned CA2988982A1 (en) | 2015-06-12 | 2016-06-11 | Anti-cd33 antibodies and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11136390B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3307771A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7376977B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180033502A (cg-RX-API-DMAC7.html) |
| CN (2) | CN107922480B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016276981B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2988982A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG10201912085WA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016201388A2 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110662765A (zh) * | 2017-08-03 | 2020-01-07 | 艾利妥 | 抗cd33抗体及其使用方法 |
| CN114174536A (zh) * | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | 抗trem-1抗体及其用途 |
| US12247073B2 (en) | 2018-08-31 | 2025-03-11 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| CN113201071A (zh) | 2017-03-28 | 2021-08-03 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| WO2018218207A1 (en) * | 2017-05-26 | 2018-11-29 | Fred Hutchinson Cancer Research Center | Anti-cd33 antibodies and uses thereof |
| BR112020000357A2 (pt) * | 2017-07-08 | 2020-07-21 | The General Hospital Corporation | plataforma de triagem para identificar fármacos ou agentes terapêuticos para o tratamento da doença de alzheimer |
| JP2021028293A (ja) * | 2017-09-21 | 2021-02-25 | 第一三共株式会社 | 免疫抑制性ミエロイド細胞マーカー |
| KR20200133222A (ko) * | 2018-02-20 | 2020-11-26 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33을 표적으로 하는 항체 가변 도메인, 및 이의 용도 |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| WO2019169448A1 (en) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Multi-specific antibodies |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| CA3106535A1 (en) | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| CN109112215A (zh) * | 2018-08-02 | 2019-01-01 | 广州安镝声生物医药科技有限公司 | lncRNA H19的靶蛋白FUS及其应用 |
| JP2022501319A (ja) * | 2018-09-25 | 2022-01-06 | アカデミア シニカAcademia Sinica | 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用 |
| CN120329441A (zh) | 2019-02-22 | 2025-07-18 | 纪念斯隆凯特琳癌症中心 | Cd33抗体和使用所述抗体治疗癌症的方法 |
| CA3136453A1 (en) * | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Humanized anti-pd-l1 antibodies |
| TW202110873A (zh) | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| AU2020329217A1 (en) * | 2019-08-12 | 2022-07-28 | Aptevo Research And Development Llc | 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40 |
| US20230035072A1 (en) * | 2019-12-12 | 2023-02-02 | Alector Llc | Methods of use of anti-cd33 antibodies |
| CN115297932A (zh) * | 2020-03-31 | 2022-11-04 | 弗莱德哈钦森癌症中心 | 抗cd33抗体和其用途 |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| WO2022234003A1 (en) * | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| CN113444687A (zh) * | 2021-05-31 | 2021-09-28 | 浙江圣希澳医学科技有限公司 | 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法 |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| GB202202171D0 (en) * | 2022-02-17 | 2022-04-06 | Bivictrix Ltd | Novel methods of therapy |
| CN114774468B (zh) * | 2022-04-20 | 2022-12-20 | 温氏食品集团股份有限公司 | 一种等位基因分子标记及抗蓝耳病猪群体组建方法 |
| US20250282852A1 (en) * | 2022-04-21 | 2025-09-11 | Sinomab Bioscience Limited | Methods of treating neurological diseases |
| CN117752813A (zh) * | 2022-09-26 | 2024-03-26 | 成都百利多特生物药业有限责任公司 | 抗cd33抗体和抗cd33抗体-药物偶联物及其用途 |
| IL320040A (en) * | 2022-10-05 | 2025-06-01 | Musc Found For Res Dev | Superantigen conjugate vaccine for cancer treatment |
| WO2024103050A1 (en) * | 2022-11-11 | 2024-05-16 | The United States Government As Represented By The Department Of Veterans Affairs | Hbv specific exosomes and uses thereof |
| AU2024249778A1 (en) * | 2023-04-03 | 2025-11-06 | Alchemab Therapeutics Ltd | Anti-cd33 antibodies |
| WO2024208836A1 (en) * | 2023-04-03 | 2024-10-10 | Universität Basel | Discernible cell surface protein variants of cd33 for use in cell therapy |
| WO2024219897A1 (ko) * | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| CN118580357A (zh) * | 2024-08-07 | 2024-09-03 | 上海交通大学医学院附属仁济医院 | 一种cd33特异性单克隆抗体及其应用 |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US769571A (en) | 1904-04-12 | 1904-09-06 | George W Snyder | Adjustable swinging gate. |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| ATE108068T1 (de) | 1987-09-23 | 1994-07-15 | Bristol Myers Squibb Co | Antikörper-heterokonjugate zur töting von hiv- infizierten zellen. |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| CA2072017A1 (en) | 1989-12-14 | 1991-06-15 | David A. Scheinberg | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| DE69132709T2 (de) | 1990-06-29 | 2002-06-20 | Large Scale Biology Corp., Vacaville | Melaninproduktion durch transformierte mikroorganismen |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| US5700922A (en) | 1991-12-24 | 1997-12-23 | Isis Pharmaceuticals, Inc. | PNA-DNA-PNA chimeric macromolecules |
| ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| ZA932523B (en) | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
| JPH08502723A (ja) | 1992-07-27 | 1996-03-26 | ハイブライドン インコーポレイテッド | オリゴヌクレオチド・アルキルホスホノチオエート |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| CN1122138A (zh) | 1993-01-21 | 1996-05-08 | 海布里顿公司 | 折回三螺旋形成寡核苷酸 |
| US5637684A (en) | 1994-02-23 | 1997-06-10 | Isis Pharmaceuticals, Inc. | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5955599A (en) | 1995-06-01 | 1999-09-21 | Hybridon, Inc. | Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages |
| US6140482A (en) | 1995-06-01 | 2000-10-31 | Hybridon, Inc. | Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same |
| US5962674A (en) | 1995-06-01 | 1999-10-05 | Hybridon, Inc. | Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages |
| US5614622A (en) | 1995-06-01 | 1997-03-25 | Hybridon, Inc. | 5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses |
| US5637683A (en) | 1995-07-13 | 1997-06-10 | Cornell Research Foundation, Inc. | Nucleic acid analog with amide linkage and method of making that analog |
| US5652356A (en) | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| WO1998008858A1 (en) | 1996-08-26 | 1998-03-05 | Hybridon, Inc. | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
| US5886165A (en) | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US5739314A (en) | 1997-04-25 | 1998-04-14 | Hybridon, Inc. | Method for synthesizing 2'-O-substituted pyrimidine nucleosides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6639059B1 (en) | 1999-03-24 | 2003-10-28 | Exiqon A/S | Synthesis of [2.2.1]bicyclo nucleosides |
| KR20010001577A (ko) | 1999-06-07 | 2001-01-05 | 윤종용 | 고분자 광산발생제를 이용한 올리고펩티드 핵산 탐침의 제조방법 |
| AU6629200A (en) | 1999-08-25 | 2001-03-19 | Philip P Garner | Alpha-helical peptide nucleic acid alpha-pna |
| MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| US6455308B1 (en) | 2001-08-01 | 2002-09-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of serum amyloid A4 expression |
| US20030206916A1 (en) | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
| US20040119010A1 (en) | 2002-11-01 | 2004-06-24 | The Regents Of The University Of Colorado | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| PT1578446E (pt) | 2002-11-07 | 2015-07-22 | Immunogen Inc | Anticorpos anti-cd33 e processo para tratamento de leucemia mieloide aguda usando os mesmos |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| MX2007008017A (es) | 2004-12-31 | 2007-09-12 | Genentech Inc | Polipeptidos que se ligan a br3 y usos de los mismos. |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200726776A (en) | 2005-07-29 | 2007-07-16 | Friedrich Alexander University Of Erlangen Nuremberg | CD33-specific single-chain immunotoxin and methods of use |
| US7420040B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| AU2007225044C1 (en) | 2006-03-15 | 2018-03-29 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| CA2667808A1 (en) | 2006-11-02 | 2008-05-15 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2193146B1 (en) | 2007-09-14 | 2016-05-25 | Adimab, LLC | Rationally designed, synthetic antibody libraries and uses therefor |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| EP2480888B1 (en) | 2009-09-25 | 2016-11-30 | XOMA Technology Ltd. | Screening methods |
| DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2012074097A1 (ja) | 2010-12-03 | 2012-06-07 | 協和発酵キリン株式会社 | 抗ｃｄ３３抗体 |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| CN102952191B (zh) * | 2012-09-17 | 2014-05-14 | 浙江大学 | 全人源抗cd33单链抗体zjl101及其应用 |
| CA2918194C (en) * | 2013-03-27 | 2022-12-06 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
| SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
| EP3227340B1 (en) * | 2014-12-04 | 2020-06-17 | Mediterranea Theranostic S.R.L. | Humanized anti-trop-2 monoclonal antibodies and uses thereof |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| PE20200486A1 (es) | 2017-08-03 | 2020-03-03 | Alector Llc | Anticuerpos anti-cd33 y metodos para utilizarlos |
-
2016
- 2016-06-11 JP JP2017564485A patent/JP7376977B2/ja active Active
- 2016-06-11 CN CN201680047246.1A patent/CN107922480B/zh active Active
- 2016-06-11 WO PCT/US2016/037108 patent/WO2016201388A2/en not_active Ceased
- 2016-06-11 AU AU2016276981A patent/AU2016276981B2/en active Active
- 2016-06-11 SG SG10201912085WA patent/SG10201912085WA/en unknown
- 2016-06-11 KR KR1020187000654A patent/KR20180033502A/ko not_active Ceased
- 2016-06-11 CA CA2988982A patent/CA2988982A1/en not_active Abandoned
- 2016-06-11 US US15/735,947 patent/US11136390B2/en active Active
- 2016-06-11 EP EP16732131.4A patent/EP3307771A2/en active Pending
- 2016-06-11 CN CN202211041145.7A patent/CN116063499A/zh active Pending
-
2020
- 2020-09-28 JP JP2020161867A patent/JP2021019599A/ja not_active Withdrawn
-
2021
- 2021-08-27 US US17/459,835 patent/US20220251190A1/en active Pending
-
2022
- 2022-06-20 JP JP2022098925A patent/JP2022137076A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110662765A (zh) * | 2017-08-03 | 2020-01-07 | 艾利妥 | 抗cd33抗体及其使用方法 |
| CN110662765B (zh) * | 2017-08-03 | 2023-09-29 | 艾利妥 | 抗cd33抗体及其使用方法 |
| US12247073B2 (en) | 2018-08-31 | 2025-03-11 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| CN114174536A (zh) * | 2019-07-15 | 2022-03-11 | 百时美施贵宝公司 | 抗trem-1抗体及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016201388A2 (en) | 2016-12-15 |
| JP2018518176A (ja) | 2018-07-12 |
| JP2021019599A (ja) | 2021-02-18 |
| HK1252697A1 (zh) | 2019-05-31 |
| JP2022137076A (ja) | 2022-09-21 |
| JP7376977B2 (ja) | 2023-11-09 |
| US20220251190A1 (en) | 2022-08-11 |
| CN107922480A (zh) | 2018-04-17 |
| WO2016201388A3 (en) | 2017-02-02 |
| AU2016276981B2 (en) | 2022-10-06 |
| CN107922480B (zh) | 2022-09-23 |
| SG10201912085WA (en) | 2020-02-27 |
| US20190002560A1 (en) | 2019-01-03 |
| US11136390B2 (en) | 2021-10-05 |
| KR20180033502A (ko) | 2018-04-03 |
| CN116063499A (zh) | 2023-05-05 |
| AU2016276981A1 (en) | 2018-01-18 |
| EP3307771A2 (en) | 2018-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220281976A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| US11667710B2 (en) | Anti-Siglec-9 antibodies and methods of use thereof | |
| US20220411503A1 (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| US20220251190A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| US20220162309A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
| US20210395361A1 (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| US12227568B2 (en) | Anti-Siglec-7 antibodies and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210610 |
|
| EEER | Examination request |
Effective date: 20210610 |
|
| EEER | Examination request |
Effective date: 20210610 |
|
| EEER | Examination request |
Effective date: 20210610 |
|
| EEER | Examination request |
Effective date: 20210610 |
|
| FZDE | Discontinued |
Effective date: 20231121 |